Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs Low Dose Bevacizumab plus Lomustine in Recurrent GBM
NCT01067469Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2010
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, lomustine in glioblastoma multiforme (GBM), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2010; status: completed.
02
Drugs
bevacizumablomustine
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01067469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01067469.